Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

News / Press Releases
: News / Press Releases

News / Press Releases

Latest News

Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting

Read Press Release

Upcoming Event

Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP)

Loews Miami Beach Hotel, Miami, FL

Oral presentation

Title: Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response
Date: Tuesday, May 30, 2017
Time: 2:10 p.m. EDT
Location: Salon 3

Poster presentation

Title: Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response (Poster Board T9)
Date: Thursday, June 1, 2017
Time: 12:30 - 2:00 p.m. EDT
Location: Salon 4